NCT05917821Not yet recruitingNot Applicable
Identification of New Antigens Against Glioblastoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS0 sites120 target enrollmentStarted: August 1, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 120
- Primary Endpoint
- Validation of the tumour specificity of the identified monoclonal antibodies
Study Overview
Brief Summary
In this study the investigators will select and develop potential therapeutic monoclonal antibodies (mAbs) for glioblastoma (GB). Activities include tissue microarray (TMA) to test monoclonal antibodies specificity and target distribution, selection of glioblastoma specific functional monoclonal antibodies, identification of candidate targets.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •age > 18 years;
- •Written informed consent
Exclusion Criteria
- •Not-availability of informed consent
Outcomes
Primary Outcomes
Validation of the tumour specificity of the identified monoclonal antibodies
Time Frame: 4 years
Candidate monoclonal antibodies will be tested by immunohistochemistry (IHC) on sections of glioblastoma tissue and healthy counterpart.
Secondary Outcomes
- Generate the single chain Fab antibody fragments (scFv) and then develop the Chimeric Antigen Receptor (CAR) T cells(4 years)
Investigators
Similar Trials
Terminated
Phase 1
Immunogene-modified T (IgT) Cells Against Glioblastoma MultiformeNCT03170141Shenzhen Geno-Immune Medical Institute30
Recruiting
Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)GlioblastomaNCT02977780David Reardon, MD460
Active, not recruiting
Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMGlioblastomaNCT02287428Dana-Farber Cancer Institute56
Unknown
Not Applicable
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing DataTranscriptomicsRadiomicsGliomaNCT04792437Yu Yao, MD120
Completed
Not Applicable
A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent NeuroblastomaRefractory NeuroblastomaRelapsed NeuroblastomaNCT01109238Giselle Sholler5